It has now settled into the 0.017-0.020 range as I predicted.The buying pressure is weakening-should stay in this range for a few months.Should think KSX wouldn't allow the buyside to disappear,so should stay in this range.
Medicine does not taste very nice,but we should take it:a biotech without proven sales revenue will always underwhelm expectations.After all,technically,this baby has been flat-lining for a long time.When our new board can provide some spark we will be away.Until then,we can only dream about universal product uptake!
Good Luck All
re:re what's to come
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)